Proliferation suppression and apoptosis of ovarian carcinoma cells induced by small interfering RNA against vascular endothelial growth factor

Journal of Obstetrics and Gynaecology Research

Volumn 36, Issue 2, 2010, Pages 232-238

  Zhou, Jianwei ^a   Gan, Ningyue ^a   Zhang, Weijiang ^a   Lu, Weiguo ^b   Xie, Xing ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Apoptosis; Ovarian carcinoma cell; Small interfering RNA; Vascular endothelial growth factor

Indexed keywords

CASPASE 3; GELATINASE A; GELATINASE B; MESSENGER RNA; SMALL INTERFERING RNA; SURVIVIN; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL LINE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; OVARY CARCINOMA; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA INTERFERENCE; TRANSIENT TRANSFECTION;

ANALYSIS OF VARIANCE; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DOWN-REGULATION; FEMALE; HUMANS; IN SITU NICK-END LABELING; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICROTUBULE-ASSOCIATED PROTEINS; OVARY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77950220455     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2010.01196.x     Document Type: Article

References (43)

1. Chen CA, Cheng WF, Lee CN et al. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: Correlation with patient survival. Gynecol Oncol 1999 74 : 235 240.
2. Gasparini G, Bonoldi E, Viale G et al. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer 1996 69 : 205 211.
3. Khalkhali-Ellis Z, Christian AL, Kirschmann DA et al. Regulating the tumor suppressor gene maspin in breast cancer cells: A potential mechanism for the anticancer properties of tamoxifen. Clin Cancer Res 2004 10 : 449 454.
4. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003 21 : 3194 3200.
5. Abu-Jawdeh GM, Jacobs TW, Niloff J et al. Estrogen receptor expression is a common feature of ovarian borderline tumors. Gynecol Oncol 1996 60 : 301 307.
6. Boocock CA, Charnock-Jones DS, Sharkey AM et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995 87 : 506 516.
7. Paley PJ, Staskus KA, Gebhard K et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997 80 : 98 106.
8. Yamamoto S, Konishi I, Mandai M et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: Correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 1997 76 : 1221 1227.
9. Chen CA, Cheng WF, Lee CN et al. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: Correlation with patient survival. Gynecol Oncol 1999 74 : 235 240.
10. Geva E, Jaffe RB. Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril 2000 74 : 429 438.
11. Grishok A, Tabara H, Mello CC. Genetic requirements for inheritance of RNAi in C. elegans. Science 2000 287 : 2494 2497.
12. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002 3 : 737 747.
13. Shi Y. Mammalian RNAi for the masses. Trends Genet 2003 19 : 9 12.
14. McCaffrey AP, Meuse L, Pham TT et al. RNA interference in adult mice. Nature 2002 418 : 38 39.
15. Novina CD, Murray MF, Dykxhoorn DM et al. siRNA-directed inhibition of HIV-1 infection. Nat Med 2002 8 : 681 686.
16. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002 2 : 243 247.
17. Minakuchi Y, Takeshita F, Kosaka N et al. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 2004 32 : e109.
18. Lakka SS, Gondi CS, Yanamandra N et al. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 2004 23 : 4681 4689.
19. Sumimoto H, Yamagata S, Shimizu A et al. Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference. Gene Ther 2005 12 : 95 100.
20. Duxbury MS, Matros E, Ito H et al. Systemic siRNA-mediated gene silencing: A new approach to targeted therapy of cancer. Ann Surg 2004 240 : 667 674.
21. Dallas A, Vlassov AV. RNAi: A novel antisense technology and its therapeutic potential. Med Sci Monit 2006 12 : RA67 RA74.
22. Cejka D, Loser T, Wacheck V. Short interfering RNA (siRNA): Tool or therapeutic? Clin Sci 2006 110 : 47 58.
23. Sui G, Soohoo C, Affarel B et al. DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 2002 99 : 5515 5520.
24. Elbashir SM, Harborth J, Lendeckel W et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001 411 : 494 498.
25. Benjamin LE, Golijanin D, Itin A et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999 103 : 159 165.
26. Alon T, Hemo I, Itin A et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995 1 : 1024 1028.
27. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 1997 94 : 8761 8766.
28. Liston P, Roy N, Tamai K et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 1996 379 : 349 353.
29. LaCasse EC, Baird S, Korneluk RG et al. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998 17 : 3247 3259.
30. Tran J, Rak J, Sheehan C et al. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 1999 264 : 781 788.
31. O'Connor DS, Schechner JS, Adida C et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 2000 156 : 393 398.
32. Mesri M, Morales-Ruiz M, Ackermann EJ et al. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol 2001 158 : 1757 1765.
33. Master Z, Yu JL, Rak J et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002 99 : 4349 4354.
34. Xu J, Rodriguez D, Petitclerc E et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 2001 154 : 1069 1079.
35. Pozzi A, Moberg PE, Miles LA et al. Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci USA 2000 97 : 2202 2207.
36. Shimada T, Nakamura H, Yamashita K et al. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human oral squamous cell carcinomas: Implications for lymph node metastasis. Clin Exp Metastasis 2000 18 : 179 188.
37. Moore DH, Allison B, Look KY et al. Collagenase expression in ovarian cancer cell lines. Gynecol Oncol 1997 65 : 78 82.
38. Sakata K, Shigemasa K, Uebaba Y et al. Expression of matrix metalloproteinases-2 and -9 by cells isolated from the peritoneal fluid of women with ovarian carcinoma. Acta Cytol 2002 46 : 697 703.
39. Schmalfeldt B, Prechtel D, Härting K et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 2001 7 : 2396 2404.
40. Munaut C, Noël A, Hougrand O et al. Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int J Cancer 2003 106 : 848 855.
41. Foda HD, Zucker S. Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. Drug Discov Today 2001 6 : 478 482.
42. Huang S, Van Arsdall M, Tedjarati S et al. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 2002 94 : 1134 1142.
43. Zhang A, Meng L, Wang Q et al. Enhanced in vitro invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2. Oncol Rep 2006 15 : 831 836.